Friday, June 10th, 2016 - Custom Market Insights

Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis (production of red blood cells). These erythropoietin (EPO) drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases (ESRD), cancer and HIV. Improved recombinant DNA technology has led to development of synthetic forms of erythropoietin such as epoetin alfa, epoetin beta, darbepoetin alfa, epoetin omega, and epoetin delta among the others. The global EPO drugs market is thus driven by increasing number of patients suffering from anemic condition induced due to cancer, HIV and ESRD treatment; favorable reimbursements and increasing commercialization of EPO biosimilars. The global EPO drugs market would reach $11.9 billion by 2020, registering CAGR of 9.7% during 2014-2020.

Amongst all synthetic erythropoietin products, Epoetin alfa and its advance version, Darbepoetin alfa, are the most popular drugs. Epoetin alfa and Darbepoetin alfa collectively accounted for ~80% of total EPO drugs market revenue. Amgen Inc. was first company to innovate Epoetin alfa and Darbepoetin alfa that are branded/patented as Epogen and Aranesp respectively. However, expiration of Amgen’s patent for Epogen has aided manufacturers of biosimilars to enter the EPO drugs market. Availability of numerous biosimilars has rendered low-cost option to the patients, therefore increased adoption rates for EPO drugs particularly in the developing regions.

Do Inquiry For Sample Report @ http://www.custommarketinsights.com/global-erythropoietin-drugs-market-products-applications-geography-size-share-global-trends-company-profiles-demand-insights-analysis-research-report-opportunities-segmentation-2-/101871#cs_tabs_request_for_sample

Based on the applications, the global EPO drugs market is segmented into anemia associated with End Stage Renal Diseases (ESRD), cancer chemotherapy and, antiretroviral treatment (ART).  Current research is focused toward expanding the applications of EPO drugs in other disease conditions such as neural diseases and wound healing.
Global EPO drugs market is segmented based on geography into North America, Europe, Asia Pacific and LAMEA. Europe is the leading geographical market owing to favorable reimbursement policies and less stringent and speedy regulatory approvals for EPO drugs.

Key companies profiled in the report are, Amgen Inc., Johnson & Johnson, Hospira Inc., Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.

Contact Profile

Custom Market Insights


Custom Market Insights is the most sufficient collection of market intelligence services online. It is your only source that can fulfill all your market research requirements.


Joel John
P: 1-855-465-4651
W: www.custommarketinsights.com

Keywords

Erythropoietin Drugs Market, Erythropoietin Drugs Industry, Erythropoietin Drugs Market 2016, Global Erythropoietin Drugs Market

Categories

Newsrooms

Sharing

More Formats